Katherine M. Nelson

Katherine M. Nelson

Auto-generated profile, based on publicly available information

Katherine M. Nelson

Department of Biomedical Engineering, University of Delaware, Newark, DE, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2016 in Plant Physiology
Verified
Journal Article
Open access
PDF file
CBCarlisle S. Bascom
Carlisle S. Bascom
SWShu-Zon Wu
Shu-Zon Wu
KNKatherine Nelson
Katherine Nelson
JOJohn S. Oakey
John S. Oakey
MBMagdalena Bezanilla
Magdalena Bezanilla
Microfluidic chambers enable imaging of moss development from early to late developmental stages at cellular and subcellular resolution.

1 August 2020 in Developmental Cell
Verified
Journal Article
Closed access
RMRichik Nilay Mukherjee
Richik Nilay Mukherjee
JSJérémy Sallé
Jérémy Sallé
SDSerge Dmitrieff
Serge Dmitrieff
KNKatherine M. Nelson
Katherine M. Nelson
JOJohn Oakey
John Oakey
DLDaniel L. Levy
Daniel L. Levy

1 April 2024 in Bioactive Materials
Verified
Journal Article
Open access
RYRachel E. Young
Rachel E. Young
KNKatherine M. Nelson
Katherine M. Nelson
SHSamuel I. Hofbauer
Samuel I. Hofbauer
TVTara Vijayakumar
Tara Vijayakumar
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
RRRachel S. Riley
Rachel S. Riley
Ionizable lipid nanoparticles (LNPs) have gained attention as mRNA delivery platforms for vaccination against COVID-19 and for protein replacement therapies. LNPs enhance mRNA stability, circulation time, cellular uptake, and preferential delivery to specific tissues compared to mRNA with no carrier platform. However, LNPs are only in the beginning stages of development for safe and effective mRNA delivery to the placenta to treat placental dysfunction. Here, we develop LNPs that enable high levels of mRNA delivery to trophoblasts in vitro and to the placenta in vivo with no toxicity. We conducted a Design of Experiments to explore how LNP composition, including the type and molar ratio of each lipid component, drives trophoblast and placental delivery. Our data revealed that utilizing C12-200 as the ionizable lipid and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as the phospholipid in the LNP design yields high transfection efficiency in vitro. Analysis of lipid molar composition as a design parameter in LNPs displayed a strong correlation between apparent pKa and poly (ethylene) glycol (PEG) content, as a reduction in PEG molar amount increases apparent pKa. Further, we present one LNP platform that exhibits the highest delivery of placental growth factor mRNA to the placenta in pregnant mice, resulting in synthesis and secretion of a potentially therapeutic protein. Lastly, our high-performing LNPs have no toxicity to both the pregnant mice and fetuses. Our results demonstrate the feasibility of LNPs as a platform for mRNA delivery to the placenta, and our top LNP formulations may provide a therapeutic platform to treat diseases that originate from placental dysfunction during pregnancy.

21 October 2019 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
PCPan Chen
Pan Chen
MTMiroslav Tomschik
Miroslav Tomschik
KNKatherine M. Nelson
Katherine M. Nelson
JOJohn Oakey
John Oakey
JGJesse Gatlin
Jesse Gatlin
DLDaniel L. Levy
Daniel L. Levy
How nuclear size is regulated relative to cell size is a fundamental cell biological question. Reductions in both cell and nuclear sizes during Xenopus laevis embryogenesis provide a robust scaling system to study mechanisms of nuclear size regulation. To test if the volume of embryonic cytoplasm is limiting for nuclear growth, we encapsulated gastrula-stage embryonic cytoplasm and nuclei in droplets of defined volume using microfluidics. Nuclei grew and reached new steady-state sizes as a function of cytoplasmic volume, supporting a limiting component mechanism of nuclear size control. Through biochemical fractionation, we identified the histone chaperone nucleoplasmin (Npm2) as a putative nuclear size effector. Cellular amounts of Npm2 decrease over development, and nuclear size was sensitive to Npm2 levels both in vitro and in vivo, affecting nuclear histone levels and chromatin organization. We propose that reductions in cell volume and the amounts of limiting components, such as Npm2, contribute to developmental nuclear size scaling.

22 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RYRachel E. Young
Rachel E. Young
KNKatherine M. Nelson
Katherine M. Nelson
SHSamuel I. Hofbauer
Samuel I. Hofbauer
TVTara Vijayakumar
Tara Vijayakumar
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
RRRachel S. Riley
Rachel S. Riley
Ionizable lipid nanoparticles (LNPs) have gained attention as mRNA delivery platforms for vaccination against COVID-19 and for protein replacement therapies. LNPs enhance mRNA stability, circulation time, cellular uptake, and preferential delivery to specific tissues compared to mRNA with no carrier platform. However, LNPs have yet to be developed for safe and effective mRNA delivery to the placenta as a method to treat placental dysfunction. Here, we develop LNPs that enable high levels of mRNA delivery to trophoblasts in vitro and to the placenta in vivo with no toxicity. We conducted a Design of Experiments to explore how LNP composition, including the type and molar ratio of each lipid component, drives trophoblast and placental delivery. Our data revealed that a specific combination of ionizable lipid and phospholipid in the LNP design yields high transfection efficiency in vitro . Further, we present one LNP platform that exhibits highest delivery of placental growth factor mRNA to the placenta in pregnant mice, which demonstrates induced protein synthesis and secretion of a therapeutic protein. Lastly, our high-performing LNPs have no toxicity to both the pregnant mice and fetuses. Our results demonstrate the feasibility of LNPs as a platform for mRNA delivery to the placenta. Our top LNPs may provide a therapeutic platform to treat diseases that originate from placental dysfunction during pregnancy.

26 June 2023 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
NIN’dEa S. Irvin-Choy
N’dEa S. Irvin-Choy
KNKatherine M. Nelson
Katherine M. Nelson
JGJason P. Gleghorn
Jason P. Gleghorn
EDEmily S. Day
Emily S. Day